Amisulpride is a highly selective D2 and D3 dopaminergic receptor blocker with no other interactions with central nervous system receptors, Amisulpride shows a robust efficacy in controlling the acute positive symptoms of schizophrenia. Compared with conventional antipsychotics, amisulpride, like other atypical antipsychotics, has a very low propensity to induce extrapyramidal side effects. In the long-term studies, a stable therapeutic response on both positive and negative symptoms is observed without significant tardive dyskinesia. Several long-term stu-dies also have confumed, In this regard, amisulpiride is classified into atypical antipsychotics. Interestingly, arni-sulpride has proved to be effective in some populations of schizophrenic patients with mainly negative symptom. (Korean J Psychopharmacol 2004;15(3):263-269)
|